Intensive Care Medicine

, Volume 33, Issue 7, pp 1199–1203

Insertion/deletion polymorphism in the promoter of NFKB1 influences severity but not mortality of acute respiratory distress syndrome

  • Michael Adamzik
  • Ulrich H. Frey
  • Kathrin Rieman
  • Stephan Sixt
  • Martin Beiderlinden
  • Winfried Siffert
  • Jürgen Peters
Brief Report

Abstract

Objective

This study investigated whether the insertion/deletion polymorphism in the promoter of NFKB1 is associated with severity and/or mortality in ARDS.

Design and setting

Prospective study in a mixed anesthesiological ICU of the University Hospital Essen.

Patients and participants

103 adult patients with ARDS (white Germans).

Measurements and results

Patients with ARDS were genotyped for the insertion/deletion polymorphism in the promoter of NFKB1 (−94ins/delATTG). In ARDS patients genotypes differed significantly between those with severe ARDS [Lung Injury Score (LIS) ≥ 3; 23 homozygote deletion (DD), heterozygote (ID) 31, and homozygote insertion wildtype (II) 23], and those with LIS below 3 (1 DD, 9 ID, 16 II). Likewise, the frequency of the D allele was significantly less in patients with higher LIS (50% D) than lower LIS (21% D). Using these values produces a significantly higher OR of 16.0 (95% CI 1.96–130.9) for DD than for II, while the OR for ID vs. II was 2.4 (95% CI 0.9–6.4). Genotypes of the NFKB1 promoter polymorphism were associated neither with 30-day survival nor with duration of ICU stay.

Conclusions

The insertion/deletion polymorphism in the promoter of NFKB1 influences the severity but not the mortality of ARDS.

Keywords

Acute respiratory distress syndrome Genotyping Insertion/deletion polymorphism NFKB1 promoter Nuclear factor κB 

References

  1. 1.
    Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R (1994) The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818–824PubMedGoogle Scholar
  2. 2.
    Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R (1994) The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818–824PubMedGoogle Scholar
  3. 3.
    Goodman RB, Strieter RM, Martin DP, Steinberg KP, Milberg JA, Maunder RJ, Kunkel SL, Walz A, Hudson LD, Martin TR (1996) Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 154:602–611PubMedGoogle Scholar
  4. 4.
    Blackwell TS, Christman JW (1997) The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 17:3–9PubMedGoogle Scholar
  5. 5.
    Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066–1071PubMedCrossRefGoogle Scholar
  6. 6.
    Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066–1071PubMedCrossRefGoogle Scholar
  7. 7.
    Madjdpour L, Kneller S, Booy C, Pasch T, Schimmer RC, Beck-Schimmer B (2003) Acid-induced lung injury: role of nuclear factor-kappaB. Anesthesiology 99:1323–1332PubMedCrossRefGoogle Scholar
  8. 8.
    Schwartz MD, Moore EE, Moore FA, Shenkar R, Moine P, Haenel JB, Abraham E (1996) Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med 24:1285–1292PubMedCrossRefGoogle Scholar
  9. 9.
    Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregersen PK, Wu Y, Achkar JP, Dassopoulos T, Mezey E, Bayless TM, Nouvet FJ, Brant SR (2004) Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 13:35–45PubMedCrossRefGoogle Scholar
  10. 10.
    Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregersen PK, Wu Y, Achkar JP, Dassopoulos T, Mezey E, Bayless TM, Nouvet FJ, Brant SR (2004) Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 13:35–45PubMedCrossRefGoogle Scholar
  11. 11.
    Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R (1994) The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818–824PubMedGoogle Scholar
  12. 12.
    Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644–1655PubMedGoogle Scholar
  13. 13.
    Le G Jr, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963CrossRefGoogle Scholar
  14. 14.
    Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754–1758PubMedCrossRefGoogle Scholar
  15. 15.
    Madjdpour L, Kneller S, Booy C, Pasch T, Schimmer RC, Beck-Schimmer B (2003) Acid-induced lung injury: role of nuclear factor-kappaB. Anesthesiology 99:1323–1332PubMedCrossRefGoogle Scholar
  16. 16.
    Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregersen PK, Wu Y, Achkar JP, Dassopoulos T, Mezey E, Bayless TM, Nouvet FJ, Brant SR (2004) Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 13:35–45PubMedCrossRefGoogle Scholar
  17. 17.
    Matsuda N, Hattori Y, Jesmin S, Gando S (2005) Nuclear factor-kappaB decoy oligodeoxynucleotides prevent acute lung injury in mice with cecal ligation and puncture-induced sepsis. Mol Pharmacol 67:1018–1025PubMedCrossRefGoogle Scholar
  18. 18.
    Sha WC, Liou HC, Tuomanen EI, Baltimore D (1995) Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 80:321–330PubMedCrossRefGoogle Scholar
  19. 19.
    Sha WC, Liou HC, Tuomanen EI, Baltimore D (1995) Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 80:321–330PubMedCrossRefGoogle Scholar
  20. 20.
    Erdman S, Fox JG, Dangler CA, Feldman D, Horwitz BH (2001) Typhlocolitis in NF-kappa B-deficient mice. J Immunol 166:1443–1447PubMedGoogle Scholar
  21. 21.
    Baer M, Dillner A, Schwartz RC, Sedon C, Nedospasov S, Johnson PF (1998) Tumor necrosis factor alpha transcription in macrophages is attenuated by an autocrine factor that preferentially induces NF-kappaB p50. Mol Cell Biol 18:5678–5689PubMedGoogle Scholar
  22. 22.
    Ziegler-Heitbrock HW, Wedel A, Schraut W, Strobel M, Wendelgass P, Sternsdorf T, Bauerle PA, Haas JG, Riethmuller G (1994) Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. J Biol Chem 269:17001–17004PubMedGoogle Scholar
  23. 23.
    Ziegler-Heitbrock HW, Petersmann I, Frankenberger M (1997) p50 (NF-kappa B1) is upregulated in LPS tolerant P388D1 murine macrophages. Immunobiology 198:73–80PubMedGoogle Scholar
  24. 24.
    Zilberberg MD, Epstein SK (1998) Acute lung injury in the medical ICU: comorbid conditions, age, etiology, and hospital outcome. Am J Respir Crit Care Med 157:1159–1164PubMedGoogle Scholar
  25. 25.
    Sloane PJ, Gee MH, Gottlieb JE, Albertine KH, Peters SP, Burns JR, Machiedo G, Fish JE (1992) A multicenter registry of patients with acute respiratory distress syndrome. Physiology and outcome. Am Rev Respir Dis 146:419–426PubMedGoogle Scholar
  26. 26.
    Doyle RL, Szaflarski N, Modin GW, Wiener-Kronish JP, Matthay MA (1995) Identification of patients with acute lung injury. Predictors of mortality. Am J Respir Crit Care Med 152:1818–1824PubMedGoogle Scholar
  27. 27.
    Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B, Doerschuk CM, Floros J, Gimbrone MA Jr, Hoffman E, Hubmayr RD, Leppert M, Matalon S, Munford R, Parsons P, Slutsky AS, Tracey KJ, Ward P, Gail DB, Harabin AL (2003) Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 167:1027–1035PubMedCrossRefGoogle Scholar
  28. 28.
    Doyle RL, Szaflarski N, Modin GW, Wiener-Kronish JP, Matthay MA (1995) Identification of patients with acute lung injury. Predictors of mortality. Am J Respir Crit Care Med 152:1818–1824PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Michael Adamzik
    • 1
    • 2
  • Ulrich H. Frey
    • 1
    • 2
  • Kathrin Rieman
    • 1
  • Stephan Sixt
    • 2
  • Martin Beiderlinden
    • 2
  • Winfried Siffert
    • 1
  • Jürgen Peters
    • 2
  1. 1.Institut für Pharmakogenetik, University Hospital EssenUniversity of Duisburg-EssenEssenGermany
  2. 2.Klinik für Anästhesiologie und Intensivmedizin, University Hospital EssenUniversity of Duisburg-EssenEssenGermany

Personalised recommendations